Novo Nordisk presented the full Phase 3 results for CagriSema in type 2 diabetes at the American Diabetes Association meeting on June 5, and the data answer a question the drug's name has been dodging: what does the second ingredient actually buy? The short version is a lot of extra weight loss and almost no extra blood-sugar control.
CagriSema is two drugs in one weekly shot. One is semaglutide ↗, the GLP-1 medicine sold as Ozempic and Wegovy. The other is cagrilintide ↗, an experimental drug that mimics amylin, a gut hormone that works alongside insulin to signal fullness. The bet behind the combination is that two appetite hormones stacked together beat either one alone. REIMAGINE 2 is the first large trial that put that bet to a clean head-to-head test in people with diabetes.
What the trial found
The trial enrolled 2,728 adults with type 2 diabetes whose blood sugar was not controlled on metformin, with or without a second standard drug. Over 68 weeks, the readout Novo first reported in February ↗ and detailed in full at ADA showed CagriSema cutting HbA1c by 1.91 percentage points and body weight by 14.2 percent. HbA1c is the standard three-month average of blood sugar, and a near-two-point drop from a starting average of 8.2 percent is a strong result on its own.
The number that matters is the comparison. Semaglutide alone, the same drug minus the amylin half, cut HbA1c by 1.76 points and weight by 10.2 percent. So adding cagrilintide bought four extra percentage points of weight loss, roughly 40 percent more than semaglutide managed by itself, while the blood-sugar improvement barely moved, a difference of 0.15 of a point. The placebo group, for scale, lost 1.5 percent of its weight and saw blood sugar tick slightly up.
The weight effect was deep enough to clear the bars that matter to patients. Forty-three percent of people on CagriSema lost at least 15 percent of their body weight, and 24 percent lost at least 20 percent, territory that used to belong to bariatric surgery.
Why the split is the story
The asymmetry is the finding, not a footnote. Amylin and GLP-1 both suppress appetite, and in the body's plumbing they converge on eating less rather than on the insulin and glucose machinery directly. So a drug that adds an amylin agonist on top of a GLP-1 agonist should, in theory, push hardest on the weight side and add little on the pure glycemic side. REIMAGINE 2 is the cleanest confirmation yet that this is how the math works in actual patients, because it isolated the amylin contribution against the same GLP-1 backbone.
That distinction is worth holding onto as the next wave of obesity drugs arrives. The GLP-1 receptor ↗ is the appetite-and-glucose switch the whole class was built on. The amylin receptor ↗ is the newer target the field is now stacking on top, and several companies are racing standalone amylin drugs and combinations into late-stage trials. REIMAGINE 2 puts a number on what the amylin half delivers when it rides along: weight, mostly.
The caveats
The comparison is against semaglutide 2.4 mg, the high obesity dose, which is the fair test. The side-effect profile was the familiar GLP-1 story, with mostly mild-to-moderate nausea and other gut complaints that faded over time, and the published readout did not break the discontinuation rate out by arm in the topline. The trial also measured efficacy, not the cardiovascular and kidney outcomes that decide a diabetes drug's long-term place, which take separate and longer studies.
For now the practical read is straightforward. If the goal is glucose control, semaglutide on its own already does most of the work. If the goal is weight, the amylin add-on is where the extra pounds come off. CagriSema is the first Phase 3 in diabetes to show exactly where that line falls.